Sanya M Wadhwa, MD
Gastroenterology · Oakland
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 21
- 4 carriers
- Offices
- 3
Offices
3 locations · East Bay Center for Digestive Health Medical Associates Inc · Alameda Health System · County of Santa Clara
Hospitals listed: Alta Bates Summit Medical Center · Highland Hospital. That is not proof they admit you there this week.
Plans that list them
21 plans · 4 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Wadhwa’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
21 of 21 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Anthem Full Dual Advantage Aligned (HMO D-SNP) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Anthem Medicare Advantage (HMO-POS) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Imperial Courage Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Dynamic Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Senior Value (HMO C-SNP) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
California Medical Board record
Licence A145736 · Current
Licensed to practise in California · since 2016 · expires 2028-10-31 · St. George'S University School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Alta Bates Summit Medical CenterOakland, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 3 of 5 · 78% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Death rate among surgical inpatients with serious treatable complications: 130.09 (87.72 to 172.46) · 109 cases, Jul 2022 – Jun 2024Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.274, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.227, Oct 2024 – Sep 2025
- Highland HospitalOakland, CAAcute Care Hospital · Government - Hospital District or Authority · Has an emergency department · Birthing-friendlyPart of Alameda Health System, which runs 4 hospitalsPatients rate it 3 of 5 · 70% would definitely recommend itOverall rating: 1 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.568, Oct 2024 – Sep 2025
See every measure and the patient survey for Alta Bates Summit Medical Center
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 4 better, 3 the same, 0 worse of 7 measures. Readmissions: 3 better, 6 the same, 0 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 130.09 (87.72 to 172.46) · 109 cases | Better | Jul 2022 – Jun 2024 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.274 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.227 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1 (0.06 to 1.94) · 1,209 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.88 (0.6 to 1.16) | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2 · 89 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.9 · 105 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.8 · 270 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.9 · 447 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13.7 · 341 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 11.2 · 381 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.6 · 2,811 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.31) · 7,167 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.21 (0.02 to 0.4) · 7,659 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.93 (0.92 to 4.94) · 1,668 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.25 (0 to 2.75) · 580 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.67 (1.19 to 4.15) · 1,446 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 6.17 (0.33 to 12.02) · 633 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 8.11 (4.67 to 11.55) · 619 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.61 (0.15 to 3.07) · 309 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.39 (0 to 0.96) · 6,085 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.8 · 217 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.724 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.425 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.716 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 12.7 · 416 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.6 · 606 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -30.4 · 359 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -31.8 · 555 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -14.4 · 358 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16 · 382 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.1 (3.2 to 8.2) · 25 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.8 (7.3 to 16) · 25 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 4.5 · 232 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.9 · 56 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20 · 152 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 14.8 (11.1 to 20) · 251 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.2 (0.9 to 1.5) · 579 cases | No different | Jan 2024 – Dec 2024 |
What patients said (535 patients answered, 18% of those asked)
| Cleanliness | 4 |
| Nurse communication | 3 |
| Doctor communication | 4 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 5 |
| Room was "always" clean | 73% |
| Nurses "always" communicated well | 75% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 58% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 87% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 79% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 75% |
| Staff "always" explained new medications | 73% |
| Nurses "always" explained things so they could understand | 69% |
| Nurses "always" listened carefully | 72% |
| Nurses "always" treated them with courtesy and respect | 85% |
| "Always" quiet at night | 54% |
| "YES", patients would definitely recommend the hospital | 78% |
| Staff "always" explained possible side effects | 43% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
See every measure and the patient survey for Highland Hospital
Behind the star rating — Deaths: 0 better, 7 the same, 0 worse of 7 measures. Safety: 0 better, 5 the same, 1 worse of 6 measures. Readmissions: 0 better, 6 the same, 3 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0 | Better | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.568 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.95 (0 to 1.99) · 487 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.06 (0.7 to 1.42) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 198.35 (145.43 to 251.26) · 50 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 6.8 · 83 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.8 · 60 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 13.3 · 148 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 11.9 · 237 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.7 · 68 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.3 · 1,143 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.17 (0 to 0.38) · 4,370 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.27 (0.07 to 0.47) · 4,344 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.54 (0.29 to 4.79) · 689 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2.07 (0.37 to 3.78) · 165 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.91 (0.34 to 3.48) · 681 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 11.62 (2.72 to 20.53) · 179 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.44 (1.37 to 9.5) · 163 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.97 (0.49 to 3.45) · 126 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.76 (0.07 to 1.44) · 3,387 cases | No different | Jul 2022 – Jun 2024 |
| MRSA BacteremiaInfections | 0.519 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.682 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.5 · 51 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 21.9 · 184 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 141.8 · 59 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 27.6 · 186 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 35.3 · 253 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.6 · 243 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5 (3.2 to 7.7) · 64 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 13.5 (9.7 to 18.5) · 64 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19 · 107 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 14.4 (10.8 to 19.4) · 355 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.5) · 84 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,960 patients answered, 26% of those asked)
| Cleanliness | 3 |
| Nurse communication | 2 |
| Doctor communication | 3 |
| Communication about medicines | 2 |
| Discharge information | 2 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 4 |
| Room was "always" clean | 68% |
| Nurses "always" communicated well | 72% |
| Doctors "always" communicated well | 77% |
| Staff "always" explained | 55% |
| Yes, staff "did" give patients this information | 83% |
| Yes, staff "did" give patients information about help after discharge | 83% |
| Doctors "always" explained things so they could understand | 73% |
| Doctors "always" listened carefully | 76% |
| Doctors "always" treated them with courtesy and respect | 82% |
| Patients who gave a rating of "9" or "10" (high) | 68% |
| Staff "always" explained new medications | 68% |
| Nurses "always" explained things so they could understand | 68% |
| Nurses "always" listened carefully | 68% |
| Nurses "always" treated them with courtesy and respect | 78% |
| "Always" quiet at night | 50% |
| "YES", patients would definitely recommend the hospital | 70% |
| Staff "always" explained possible side effects | 42% |
| Yes, staff "did" give patients information about possible symptoms | 82% |
Original Medicare doctor bills
$75,896
Medicare paid this office $75,896 for 335 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 91 | $22,008 | $239 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 102 | $9,513 | $92 |
| New patient visit (45+ min) | 74 | $8,045 | $109 |
| Return visit (30+ min) | 58 | $6,794 | $98 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 46 | $5,383 | $117 |
See all 14 services
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 91 | $22,008 | $239 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 102 | $9,513 | $92 |
| New patient visit (45+ min) | 74 | $8,045 | $109 |
| Return visit (30+ min) | 58 | $6,794 | $98 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 46 | $5,383 | $117 |
| Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | 24 | $4,836 | $186 |
| Colorectal cancer screening; colonoscopy on individual at high risk | 20 | $3,987 | $199 |
| Diagnostic exam of large bowel using a flexible endoscope | 27 | $3,874 | $143 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 24 | $2,509 | $72 |
| Biopsy of large bowel using a flexible endoscope | 23 | $2,244 | $98 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 13 | $1,476 | $105 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 11 | $1,408 | $108 |
| Short return visit (20+ min) | 12 | $877 | $67 |
| New patient visit (30+ min) | 11 | $274 | $25 |
Procedures Medicare counted
| Colonoscopy | 93 | More than 78% of doctors who do this |
| Upper gastrointestinal (GI) endoscopy for acid reflux | 136 | More than 83% of doctors who do this |
Who their Medicare patients are
335 Original Medicare patients in 2024. Average age 72 · Under 65 10% · 85 and older 8% · Women 54% · Also on Medicaid 69% · Health risk score 1.45. Above the middle of the specialty; the typical gastroenterology clinician is at 1.42.
Conditions among them: High blood pressure 70% · Diabetes 36% · Chronic kidney disease 28% · COPD 19% · Depression 18% · Coronary heart disease 16% · Heart failure 16% · Cancer 14% · Atrial fibrillation 13% · Stroke 9% · Dementia 7%.
The office billed $410,882, Medicare allowed $98,789 and paid $75,896; for 594 services of 28 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 335 | 594 | 72 | 1.45 | $410,882 | $75,896 |
| 2023 | 187 | 357 | 72 | 1.29 | $202,801 | $44,116 |
| 2022 | 356 | 751 | 74 | 1.36 | $457,278 | $82,109 |
| 2021 | 229 | 532 | 72 | 2.05 | $374,048 | $66,566 |
| 2020 | 62 | 144 | 69 | 2.24 | $84,154 | $18,436 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 10 services
| Return visit (30+ min) | 73 | $9,618 | $111 |
| New patient visit (45+ min) | 71 | $9,612 | $135 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 33 | $7,383 | $224 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 38 | $3,203 | $84 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 20 | $2,553 | $116 |
| Colorectal cancer screening; colonoscopy on individual at high risk | 12 | $2,333 | $194 |
| Short return visit (20+ min) | 22 | $2,133 | $85 |
| Diagnostic exam of large bowel using a flexible endoscope | 12 | $1,749 | $146 |
| Biopsy of large bowel using a flexible endoscope | 14 | $1,186 | $85 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 12 | $999 | $71 |
2022: 11 services
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 76 | $16,358 | $215 |
| Short return visit (20+ min) | 158 | $15,450 | $72 |
| Return visit (30+ min) | 82 | $10,538 | $110 |
| New patient visit (45+ min) | 76 | $9,881 | $130 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 71 | $6,047 | $84 |
| Colorectal cancer screening; colonoscopy on individual at high risk | 27 | $5,179 | $192 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 43 | $4,634 | $108 |
| New patient visit (30+ min) | 37 | $3,450 | $93 |
| Diagnostic exam of large bowel using a flexible endoscope | 14 | $2,180 | $156 |
| Biopsy of large bowel using a flexible endoscope | 27 | $2,138 | $79 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 17 | $1,116 | $59 |
2021: 11 services
| New patient visit (45+ min) | 94 | $13,806 | $147 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 37 | $8,955 | $218 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 72 | $8,696 | $118 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 75 | $6,115 | $79 |
| Return visit (30+ min) | 32 | $4,413 | $116 |
| Short return visit (20+ min) | 41 | $3,891 | $85 |
| Telephone medical discussion with physician, 11-20 minutes | 25 | $2,606 | $87 |
| Control of bleeding of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 12 | $2,272 | $175 |
| Diagnostic exam of large bowel using a flexible endoscope | 13 | $1,927 | $148 |
| Biopsy of large bowel using a flexible endoscope | 18 | $1,626 | $90 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 15 | $1,049 | $66 |
2020: 4 services
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 23 | $2,929 | $122 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 12 | $2,822 | $235 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 20 | $1,770 | $84 |
| New patient visit (30+ min) | 14 | $1,420 | $101 |
Medicaid work
$3,280 in 2024
Medicaid paid $3,280 for 538 billed services this clinician did in 2024, up to 34 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Upper gastrointestinal endoscopy with biopsy | 179 | $1,991 |
| COLONOSCOPY W/LESION REMOVAL | 146 | $1,005 |
| DIAGNOSTIC COLONOSCOPY | 122 | $147 |
| New patient visit (45+ min) | 91 | $138 |
| 2024 | 538 | 4 | 34 | $3,280 |
| 2023 | 41 | 2 | 15 | $5,961 |
| 2022 | 13 | 1 | 13 | $2,225 |
| 2021 | 114 | 2 | 19 | $15,533 |
| 2020 | 13 | 1 | 13 | $1,200 |
See the largest Medicaid services in earlier years
2023
| New patient visit (45+ min) | 28 | $4,563 |
| Return visit (30+ min) | 13 | $1,398 |
2022
| New patient visit (45+ min) | 13 | $2,225 |
2021
| New patient visit (45+ min) | 62 | $9,368 |
| Upper gastrointestinal endoscopy with biopsy | 52 | $6,164 |
2020
| New patient visit (30+ min) | 13 | $1,200 |
Drugs they prescribed that Part D paid
$87,299
Pharmacies billed $87,299 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 530) in 2024. At or below the middle of the specialty; the typical gastroenterology clinician is at 0%.
429 generic and 101 brand-name prescriptions · $87,299 in drug cost · 12 antibiotic prescriptions.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Vemlidy | 28 | $42,360 | $1,513 |
| Gavilyte-G | 116 | $1,773 | $15 |
| Sod Sulf-Potass Sulf-Mag Sulf | 26 | $1,658 | $64 |
| Omeprazole | 83 | $1,138 | $14 |
| Pantoprazole | 70 | $657 | $9 |
See all 10 drugs
| Vemlidy | 28 | $42,360 | $1,513 |
| Gavilyte-G | 116 | $1,773 | $15 |
| Sod Sulf-Potass Sulf-Mag Sulf | 26 | $1,658 | $64 |
| Omeprazole | 83 | $1,138 | $14 |
| Pantoprazole | 70 | $657 | $9 |
| Peg-3350 and Electrolytes | 36 | $509 | $14 |
| Famotidine | 51 | $476 | $9 |
| Esomeprazole Magnesium | 11 | $446 | $41 |
| Gavilyte-C | 27 | $421 | $16 |
| Sucralfate | 12 | $137 | $11 |
Year by year
| 2024 | 530 | 309 | 0% (0) | 19% | $87,299 |
| 2023 | 618 | 257 | 0% (0) | 16% | $112,377 |
| 2022 | 939 | 339 | 0% (0) | None | $398,044 |
| 2021 | 287 | 117 | None | 43% | $69,961 |
| 2020 | 61 | 26 | 0% (0) | 41% | $6,912 |
| 2019 | 77 | 21 | 0% (0) | 17% | $8,961 |
| 2018 | 54 | 19 | 0% (0) | 22% | $3,236 |
| 2017 | 109 | 31 | None | 23% | $27,921 |
| 2015 | 137 | 18 | None | None | $7,548 |
| 2014 | 35 | None | None | None | $2,717 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 13 drugs
| Mesalamine | 19 | $25,455 | $1,340 |
| Linzess | 11 | $12,334 | $1,121 |
| Dexlansoprazole Dr | 19 | $7,417 | $390 |
| Sod Sulf-Potass Sulf-Mag Sulf | 87 | $6,935 | $80 |
| Omeprazole | 141 | $2,943 | $21 |
| Esomeprazole Magnesium | 15 | $2,173 | $145 |
| Sucralfate | 15 | $1,901 | $127 |
| Pantoprazole | 74 | $1,692 | $23 |
| Loperamide | 13 | $865 | $67 |
| Dicyclomine | 29 | $673 | $23 |
| Rabeprazole | 11 | $528 | $48 |
| Famotidine | 51 | $501 | $10 |
| Gavilyte-G | 12 | $204 | $17 |
2022: 14 drugs
| Mesalamine | 39 | $49,169 | $1,261 |
| Dexilant | 37 | $27,671 | $748 |
| Linzess | 20 | $25,216 | $1,261 |
| Suprep | 99 | $11,339 | $115 |
| Mesalamine Er | 12 | $4,322 | $360 |
| Omeprazole | 185 | $3,587 | $19 |
| Pantoprazole | 135 | $2,723 | $20 |
| Budesonide Dr | 18 | $1,894 | $105 |
| Dicyclomine | 62 | $1,744 | $28 |
| Loperamide | 25 | $1,442 | $58 |
| Sod Sulf-Potass Sulf-Mag Sulf | 17 | $1,378 | $81 |
| Sucralfate | 18 | $1,257 | $70 |
| Esomeprazole Magnesium | 21 | $1,006 | $48 |
| Famotidine | 51 | $773 | $15 |
2021: 5 drugs
| Suprep | 81 | $8,987 | $111 |
| Mesalamine Er | 12 | $6,433 | $536 |
| Omeprazole | 41 | $608 | $15 |
| Pantoprazole | 39 | $586 | $15 |
| Dicyclomine | 17 | $357 | $21 |
2020: 1 drug
| Suprep | 16 | $1,703 | $106 |
2019: 3 drugs
| Sucralfate | 11 | $238 | $22 |
| Omeprazole | 11 | $215 | $20 |
| Promethazine | 11 | $208 | $19 |
2018: 2 drugs
| Omeprazole | 11 | $212 | $19 |
| Pantoprazole | 13 | $176 | $14 |
2017: 3 drugs
| Atorvastatin | 12 | $246 | $21 |
| Losartan | 11 | $102 | $9 |
| Furosemide | 17 | $87 | $5 |
2015: 1 drug
| Amlodipine Besylate | 15 | $61 | $4 |
Money from drug and device companies
$2,368 in 2025
| 2025 | 16 | 92 | None | $2,368 |
| 2024 | 13 | 54 | None | $1,262 |
| 2023 | 6 | 13 | None | $270 |
| 2022 | 4 | 7 | None | $158 |
| 2021 | 6 | 20 | None | $229 |
| 2020 | 1 | 1 | None | $25 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Abbvie | Rinvoq | $418 | 16 payments
|
| Janssen Biotech | Tremfya | $385 | 12 payments
|
| Takeda Pharmaceuticals U.S.A. | Entyvio | $283 | 13 payments
|
| Lilly USA | Omvoh | $264 | 9 payments
|
| Gilead Sciences | None | $222 | 8 payments
|
| Ardelyx | Ibsrela | $201 | 8 payments
|
See all 92 published payments
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-12-22 | Entyvio | $35 |
| Madrigal Pharmaceuticals | Meals · 2025-12-17 | Rezdiffra | $25 |
| Aimmune Therapeutics | Meals · 2025-12-16 | Zenpep | $34 |
| Novo Nordisk | Meals · 2025-12-08 | Wegovy | $22 |
| Ipsen Biopharmaceuticals | Meals · 2025-12-05 | Iqirvo | $29 |
| Ardelyx | Meals · 2025-12-02 | Ibsrela | $26 |
| Abbvie | Meals · 2025-12-01 | Rinvoq | $28 |
| Abbvie | Meals · 2025-11-10 | Rinvoq | $26 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-11-05 | Entyvio | $21 |
| Abbvie | Meals · 2025-11-04 | Skyrizi | $25 |
| Abbvie | Meals · 2025-11-04 | Skyrizi | $23 |
| Aimmune Therapeutics | Meals · 2025-11-03 | Zenpep | $27 |
| Janssen Biotech | Meals · 2025-10-31 | Tremfya | $26 |
| Gilead Sciences | Meals · 2025-10-28 | None | $29 |
| QOL Medical | Meals · 2025-10-23 | Sucraid | $26 |
| Ipsen Biopharmaceuticals | Meals · 2025-10-20 | Iqirvo | $28 |
| Ardelyx | Meals · 2025-10-20 | Ibsrela | $29 |
| Abbvie | Meals · 2025-10-10 | Rinvoq | $27 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-10-09 | Entyvio | $19 |
| Genzyme | Meals · 2025-10-08 | Dupixent | $42 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-10-07 | Eohilia | $23 |
| Janssen Biotech | Meals · 2025-10-02 | Tremfya | $34 |
| Abbvie | Meals · 2025-10-01 | Skyrizi | $29 |
| Novo Nordisk | Meals · 2025-09-30 | Wegovy | $17 |
| QOL Medical | Meals · 2025-09-23 | Sucraid | $18 |
| Lilly USA | Meals · 2025-09-22 | Omvoh | $19 |
| Madrigal Pharmaceuticals | Meals · 2025-09-06 | Rezdiffra | $25 |
| Janssen Biotech | Meals · 2025-09-04 | Tremfya | $32 |
| Abbvie | Meals · 2025-08-27 | Rinvoq | $24 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-08-26 | Entyvio | $18 |
| Ardelyx | Meals · 2025-08-25 | Ibsrela | $25 |
| Lilly USA | Meals · 2025-08-20 | Omvoh | $21 |
| Gilead Sciences | Meals · 2025-08-19 | None | $34 |
| Janssen Biotech | Meals · 2025-08-18 | Tremfya | $39 |
| Lilly USA | Meals · 2025-08-04 | Omvoh | $33 |
| Gilead Sciences | Meals · 2025-08-04 | None | $26 |
| Lilly USA | Meals · 2025-07-31 | Omvoh | $34 |
| Lilly USA | Meals · 2025-07-31 | Omvoh | $29 |
| Madrigal Pharmaceuticals | Meals · 2025-07-30 | Rezdiffra | $13 |
| Intercept Pharmaceuticals | Meals · 2025-07-29 | Ocaliva | $20 |
| Intercept Pharmaceuticals | Meals · 2025-07-25 | Ocaliva | $17 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-07-23 | Entyvio | $36 |
| Gilead Sciences | Meals · 2025-07-22 | None | $30 |
| QOL Medical | Meals · 2025-07-16 | Sucraid | $20 |
| Abbvie | Meals · 2025-07-15 | Rinvoq | $30 |
| Janssen Biotech | Meals · 2025-07-14 | Tremfya | $29 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-07-11 | Entyvio | $18 |
| Madrigal Pharmaceuticals | Meals · 2025-06-28 | Rezdiffra | $7 |
| Abbvie | Meals · 2025-06-26 | Rinvoq | $27 |
| Ardelyx | Meals · 2025-06-24 | Ibsrela | $33 |
| Madrigal Pharmaceuticals | Meals · 2025-06-19 | Rezdiffra | $26 |
| Abbvie | Meals · 2025-06-18 | Rinvoq | $27 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-06-17 | Entyvio | $25 |
| Janssen Biotech | Meals · 2025-06-16 | Tremfya | $32 |
| Janssen Biotech | Education · 2025-05-30 | Tremfya | $51 |
| Abbvie | Meals · 2025-05-29 | Skyrizi | $23 |
| Gilead Sciences | Meals · 2025-05-28 | None | $33 |
| Ardelyx | Meals · 2025-05-27 | Ibsrela | $25 |
| Gilead Sciences | Meals · 2025-05-23 | None | $31 |
| Biocon Biologics | Meals · 2025-05-22 | Yesintek | $30 |
| Intercept Pharmaceuticals | Meals · 2025-05-20 | Ocaliva | $21 |
| Intercept Pharmaceuticals | Meals · 2025-05-13 | Ocaliva | $21 |
| Gilead Sciences | Meals · 2025-05-12 | None | $8 |
| Madrigal Pharmaceuticals | Meals · 2025-05-09 | Rezdiffra | $23 |
| Abbvie | Meals · 2025-05-06 | Creon | $19 |
| Janssen Biotech | Meals · 2025-05-05 | Tremfya | $28 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-04-25 | Entyvio | $13 |
| Lilly USA | Meals · 2025-04-23 | Omvoh | $26 |
| Janssen Biotech | Meals · 2025-04-18 | Tremfya | $18 |
| Gilead Sciences | Meals · 2025-04-18 | None | $32 |
| Celltrion USA | Meals · 2025-04-16 | Vegzelma | $18 |
| Janssen Biotech | Meals · 2025-04-14 | Tremfya | $39 |
| Abbvie | Meals · 2025-04-02 | Rinvoq | $32 |
| Lilly USA | Meals · 2025-03-28 | Omvoh | $35 |
| Ardelyx | Meals · 2025-03-27 | Ibsrela | $26 |
| Lilly USA | Meals · 2025-03-24 | Omvoh | $35 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-03-14 | Entyvio | $12 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-03-13 | Entyvio | $22 |
| Abbvie | Meals · 2025-03-11 | Linzess | $17 |
| Madrigal Pharmaceuticals | Meals · 2025-03-04 | Rezdiffra | $20 |
| Madrigal Pharmaceuticals | Meals · 2025-03-03 | Rezdiffra | $18 |
| Janssen Biotech | Meals · 2025-02-27 | Tremfya | $30 |
| Janssen Biotech | Meals · 2025-02-24 | Tremfya | $26 |
| Ardelyx | Meals · 2025-02-20 | Ibsrela | $20 |
| Abbvie | Meals · 2025-02-19 | Skyrizi | $32 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-02-18 | Entyvio | $23 |
| Braintree Laboratories | Meals · 2025-02-04 | Sutab | $19 |
| Madrigal Pharmaceuticals | Meals · 2025-02-03 | Rezdiffra | $29 |
| Ardelyx | Meals · 2025-01-28 | Ibsrela | $16 |
| Lilly USA | Meals · 2025-01-15 | Omvoh | $33 |
| Abbvie | Meals · 2025-01-09 | Skyrizi | $29 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-01-06 | Entyvio | $17 |
See earlier years (2024, 2023, 2022, 2021, 2020)
2024: $1,262
| Abbvie | Rinvoq | $284 | 15 payments
|
| Janssen Biotech | Stelara | $259 | 10 payments
|
| Lilly USA | Omvoh | $229 | 8 payments
|
| QOL Medical | Sucraid | $129 | 7 payments
|
| Intuitive Surgical | Da Vinci Surgical System | $68 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Andexxa | $66 | 3 payments
|
| Ardelyx | Ibsrela | $63 | 2 payments
|
| Takeda Pharmaceuticals U.S.A. | Entyvio | $54 | 3 payments
|
| Phathom Pharmaceuticals | Voquezna | $29 | 1 payment
|
| Aimmune Therapeutics | Vowst | $29 | 1 payment
|
| Regeneron Healthcare Solutions | Dupixent | $23 | 1 payment
|
| Salix Pharmaceuticals a division of Bausch Health US | Trulance | $15 | 1 payment
|
| Gilead Sciences | None | $15 | 1 payment
|
2023: $270
| AbbVie | Rinvoq | $133 | 6 payments
|
| QOL Medical | Sucraid | $40 | 2 payments
|
| Genzyme | Dupixent | $35 | 2 payments
|
| Janssen Biotech | Stelara | $33 | 1 payment
|
| Boston Scientific | None | $15 | 1 payment
|
| Celgene | Zeposia | $14 | 1 payment
|
2022: $158
| Abbvie | Humira | $69 | 3 payments
|
| Salix Pharmaceuticals a division of Bausch Health US | Xifaxan | $39 | 2 payments
|
| Janssen Biotech | Stelara | $28 | 1 payment
|
| Genzyme | Dupixent | $23 | 1 payment
|
2021: $229
| AbbVie | Humira | $121 | 15 payments
|
| Janssen Biotech | Stelara | $28 | 1 payment
|
| Salix Pharmaceuticals a division of Bausch Health US | Xifaxan | $22 | 1 payment
|
| Pfizer | Xeljanz | $20 | 1 payment
|
| Ethicon US | None | $19 | 1 payment
|
| Takeda Pharmaceuticals U.S.A. | Motegrity | $19 | 1 payment
|
2020: $25
| AbbVie | Humira | $25 | 1 payment
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 80.6 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1003234501
- Licence
- CA A145736California A145736: Current · expires 2028-10-31
- Group
- East Bay Center for Digestive Health Medical Associates Inc · Alameda Health System · County of Santa Clara
- Gender
- Female
More record details
- Sole proprietor
- Yes
- Taxonomy
- Federal specialty code 207RG0100X (207RG0100X); Student in a training program (390200000X)
- Mailing address
- 300 Frank H Ogawa Plz Ste 355, Oakland, CA, 94612
- NPI first listed
- 2014-04-01
- NPI last updated
- 2024-01-02
- NPI record certified
- 2024-01-02
This is when the NPI record was last certified, not a medical board exam.